Twice-a-Year HIV Shot Hailed as Breakthrough—But Big Pharma Price Tag Could Leave Millions Behind

A new HIV prevention drug, lenacapavir, administered as a twice-yearly injection, is being hailed as a potential pivotal factor in the fight against HIV. Developed by pharmaceutical company Gilead Sciences, the drug has shown high efficacy in clinical trials, offering a convenient alternative to daily pills. However, its availability remains uncertain, particularly in low- and middle-income countries where the burden of HIV is greatest.

Lenacapavir works by blocking the HIV capsid protein, disrupting the virus's ability to replicate. In trials, it reduced HIV infections by over 90% among cisgender women and showed promising results in other populations. Despite these results, the drug's high cost—estimated at over $40,000 per year in the U.S.—and limited manufacturing capacity raise concerns about equitable access. Global health advocates are urging Gilead to license the drug for generic production and set affordable prices for developing nations.

The World Health Organization and UNAIDS have emphasized the need for widespread access to lenacapavir, warning that without it, the HIV epidemic could persist in vulnerable communities. Gilead has stated it is committed to making the drug accessible, but concrete plans for low-income countries have yet to be announced. As regulatory approvals are sought, the coming months will be critical in determining whether this breakthrough reaches those who need it most.